within Pharmacolibrary.Drugs.ATC.R;

model R03AC11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.21,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.0038,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Tulobuterol is a long-acting beta2-adrenergic receptor agonist used as a bronchodilator for the treatment of bronchial asthma, chronic bronchitis, and other chronic obstructive pulmonary diseases. It is often administered as a transdermal patch and is approved for use in several countries, including Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a healthy adult population after transdermal administration, as published data are very limited.</p><h4>References</h4><ol><li><p>Kim, JH, et al., &amp; Seo, KW (2016). The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. <i>Veterinary journal (London, England : 1997)</i> 208 90–92. DOI:<a href=&quot;https://doi.org/10.1016/j.tvjl.2015.10.012&quot;>10.1016/j.tvjl.2015.10.012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26639828/&quot;>https://pubmed.ncbi.nlm.nih.gov/26639828</a></p></li><li><p>Takizawa, Y, et al., &amp; Fukai, F (2017). Skin permeability of tulobuterol in two transdermal formulations and their followability. <i>Drug discoveries &amp; therapeutics</i> 11(5) 253–258. DOI:<a href=&quot;https://doi.org/10.5582/ddt.2017.01050&quot;>10.5582/ddt.2017.01050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29021505/&quot;>https://pubmed.ncbi.nlm.nih.gov/29021505</a></p></li><li><p>Park, SI, &amp; Kim, BH (2018). Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects . <i>International journal of clinical pharmacology and therapeutics</i> 56(8) 381–386. DOI:<a href=&quot;https://doi.org/10.5414/CP203268&quot;>10.5414/CP203268</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29932416/&quot;>https://pubmed.ncbi.nlm.nih.gov/29932416</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AC11;
